[News Space=Reporter seungwon lee] Samsung BioLogics is drastically reorganizing its business structure through a spin-off. On the 22nd, Samsung BioLogics announced through a public disclosure that it will split the company into the surviving corporation, ‘Samsung BioLogics’, which will be in charge of the contract development and manufacturing organization (CDMO) business, and the newly established corporation, ‘Samsung Epi Holdings’, which will act as an investment and holding company for biosimilar and new drug development. This split is a strategic decision to strengthen the expertise and
[News Space=Reporter seungwon lee] Naver Chairman Lee Hae-jin met with NVIDIA CEO Jensen Huang in Taiwan and signaled a new phase in the global AI leadership competition. This meeting was held during Asia's largest IT exhibition, 'Computex 2025', and NVIDIA's cloud partner event, 'NPC Summit', and the discussion on 'Sovereign AI' cooperation, which combines Naver's AI strategy and NVIDIA's infrastructure, emerged as a key agenda. Naver executives mobilize to attack Southeast Asia AI market in earnest Chairman Lee Hae-jin visited Taiwan with key executives, including Naver CEO Choi Soo-yeon and
[News Space=Reporter seungwon lee] Osstem Pharma (CEO Moon Byeong-jeom), a subsidiary of Osstem Implant, announced that it received enthusiastic interest and response by introducing an exhibition booth for its premium oral care brand 'Viewsen' at the 'China Beauty Expo 2025 (CBE)' held at the Shanghai International Expo Center from May 12 to 14. CBE is the largest beauty trade show in Asia. This year, in its 29th year, over 3,500 companies from 80 countries around the world opened booths and attracted over 500,000 visitors. Osstem Pharma set up a brand promotion booth centered around the Views
[News Space=Reporter seungwon lee] Despite the increase in sales in 2024, Novartis Korea (CEO Yoo Byung-jae) saw its profitability decline as both operating profit and net profit decreased. The operating profit ratio also fell to 3.7%. In addition, short-term borrowings increased and cash assets remain at 0 won, making liquidity management weak. The scale of purchases and debts with special related parties (head office, etc.) is large, and the financial structure has improved somewhat due to inventory asset reduction and restructuring (dramatic reduction in retirement benefits), but the group
[News Space=Reporter seungwon lee] Celltrion has successfully expanded its coverage by signing a formulary listing contract for its autoimmune disease treatment drug 'Steqeyma' (ingredient name: ustekinumab) with one of the top five prescription drug benefit managers (PBM) in the United States. As Celltrion secures the private insurance area under the jurisdiction of the PBM through this contract, Stekima is scheduled to receive a refund starting July 1. This contract is the second achievement that Celltrion has made with a large US PBM for the listing of Stekima in the formulary. Prior to thi
[News Space=Reporter seungwon lee] Daewon Pharmaceutical, once the pride of domestic new drugs, has lost four consecutive patent lawsuits for ‘Pelubi’ from the first trial to the Supreme Court, exposing its management incompetence and structural risks at once. In recent years, Daewon Pharmaceutical has been criticized as a typical ‘bad company’ due to repeated investigations by the Ministry of Food and Drug Safety and the National Tax Service, as well as repeated defeats in court. ◆ Four consecutive patent lawsuit losses… The fall of the Pelubi myth Daewon Pharmaceutical’s domestic new drug ‘P
서울시 서초구 사평대로 140 코웰빌딩 B1, 318호 | 대표전화 : 0505-546-0505 | 팩스 : 0505-548-0505
제호 : 뉴스스페이스(NewsSpace) | 등록번호 : 서울 아 54727 | 등록일 : 2023-03-07 | 발행일 : 2023-03-07 | 발행·편집인 : 이현주 | 청소년보호책임자 : 김정영
Copyright © 2024 뉴스스페이스(NewsSpace). All rights reserved.
UPDATE: 2025년 06월 16일 23시 43분
